Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 52% over the past four weeks to close the last trading session at 5.41,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof35.50 indicates a potential upside of 556.2%.The mean estimate comprises six short-term price targets with a standard deviation of 23.86.Whilethelowestestimateof3 indicates a 44.6% dec ...